Analyst Price Target is $12.00
▲ +183.02% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Liquidia in the last 3 months. The average price target is $12.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 183.02% upside from the last price of $4.24.
Current Consensus is
The current consensus among 5 polled investment analysts is to buy stock in Liquidia. This Buy consensus rating has held steady for over two years.
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.